Therefore, combination therapy with SGLT-2 inhibitors and Pio is reasonable because these two kinds of anti-hyperglycemic agents have CV benefits, whereas SGLT-2 inhibitors may lower the risks of HF associated with Pio. Here, SLC5A2 is linked to hydrops fetalis.